Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Network Meta-analysis of Progression-Free Survival and Overall Survival in First-Line Treatment of BRAF Mutation-Positive Metastatic Melanoma

Network Meta-analysis of Progression-Free Survival and Overall Survival in First-Line Treatment... Oncol Ther (2016) 4:239–256 DOI 10.1007/s40487-016-0030-2 ORIGINAL RESEARCH Network Meta-analysis of Progression-Free Survival and Overall Survival in First-Line Treatment of BRAF Mutation-Positive Metastatic Melanoma . . Jordan Amdahl Lei Chen Thomas E. Delea Received: May 18, 2016 / Published online: September 27, 2016 The Author(s) 2016. This article is published with open access at Springerlink.com systematic literature reviews. HRs for PFS and ABSTRACT OS (adjusted for crossover as appropriate) were Introduction: The present study aimed to analyzed using multivariate and univariate inform an economic evaluation of dabrafenib Bayesian network meta-analysis. and trametinib combination as first-line Results: In multivariate network-meta analyses treatment of metastatic melanoma in a (HRs for PFS and OS estimated simultaneously Canadian setting. A network meta-analysis was to account for the correlation of treatment conducted to estimate hazard ratios (HRs) for effects on PFS and OS), HRs (95% credible progression-free survival (PFS)and overall interval) for PFS and OS favored dabrafenib survival (OS) of dabrafenib plus trametinib plus trametinib [PFS: 0.23 (0.18–0.29) versus versus other first-line treatments of BRAF DTIC, 0.32 (0.24–0.42) versus ipilimumab plus mutation-positive metastatic melanoma DTIC, 0.52 (0.32–0.83) versus trametinib, 0.57 including dabrafenib, trametinib, vemurafenib, (0.48–0.69) versus vemurafenib, and 0.59 ipilimumab, and dacarbazine (DTIC). (0.50–0.71) http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Network Meta-analysis of Progression-Free Survival and Overall Survival in First-Line Treatment of BRAF Mutation-Positive Metastatic Melanoma

Amdahl, Jordan; Chen, Lei; Delea, Thomas
Oncology and Therapy , Volume 4 (2) – Sep 27, 2016
Download PDF
18 pages

Loading next page...
 
/lp/springer-journals/network-meta-analysis-of-progression-free-survival-and-overall-rsQFisYRUR
Publisher
Springer Journals
Copyright
Copyright © 2016 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-016-0030-2
Publisher site
See Article on Publisher Site

Abstract

Oncol Ther (2016) 4:239–256 DOI 10.1007/s40487-016-0030-2 ORIGINAL RESEARCH Network Meta-analysis of Progression-Free Survival and Overall Survival in First-Line Treatment of BRAF Mutation-Positive Metastatic Melanoma . . Jordan Amdahl Lei Chen Thomas E. Delea Received: May 18, 2016 / Published online: September 27, 2016 The Author(s) 2016. This article is published with open access at Springerlink.com systematic literature reviews. HRs for PFS and ABSTRACT OS (adjusted for crossover as appropriate) were Introduction: The present study aimed to analyzed using multivariate and univariate inform an economic evaluation of dabrafenib Bayesian network meta-analysis. and trametinib combination as first-line Results: In multivariate network-meta analyses treatment of metastatic melanoma in a (HRs for PFS and OS estimated simultaneously Canadian setting. A network meta-analysis was to account for the correlation of treatment conducted to estimate hazard ratios (HRs) for effects on PFS and OS), HRs (95% credible progression-free survival (PFS)and overall interval) for PFS and OS favored dabrafenib survival (OS) of dabrafenib plus trametinib plus trametinib [PFS: 0.23 (0.18–0.29) versus versus other first-line treatments of BRAF DTIC, 0.32 (0.24–0.42) versus ipilimumab plus mutation-positive metastatic melanoma DTIC, 0.52 (0.32–0.83) versus trametinib, 0.57 including dabrafenib, trametinib, vemurafenib, (0.48–0.69) versus vemurafenib, and 0.59 ipilimumab, and dacarbazine (DTIC). (0.50–0.71)

Journal

Oncology and Therapy – Springer Journals

Published: Sep 27, 2016

References

  • Improved survival with ipilimumab in patients with metastatic melanoma
    Hodi, FS; O’Day, SJ; McDermott, DF; Weber, RW; Sosman, JA; Haanen, JB
  • Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma
    Schadendorf, D; Hodi, FS; Robert, C; Weber, JS; Margolin, K; Hamid, O
  • Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
    Robert, C; Thomas, L; Bondarenko, I; O’Day, S; Weber, J; Garbe, C
  • Pembrolizumab versus ipilimumab in advanced melanoma
    Robert, C; Schachter, J; Long, GV; Arance, A; Grob, JJ; Mortier, L
  • Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
    Postow, MA; Chesney, J; Pavlick, AC; Robert, C; Grossmann, K; McDermott, D
  • Combined nivolumab and ipilimumab or monotherapy in untreated melanoma
    Larkin, J; Hodi, FS; Wolchok, JD
  • Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma
    Wang, AX; Qi, XY
  • Improved survival with vemurafenib in melanoma with BRAF V600E mutation
    Chapman, PB; Hauschild, A; Robert, C; Haanen, JB; Ascierto, P; Larkin, J
  • Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
    McArthur, GA; Chapman, PB; Robert, C; Larkin, J; Haanen, JB; Dummer, R
  • Vemurafenib for the treatment of locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma: a NICE single technology appraisal
    Beale, S; Dickson, R; Bagust, A; Blundell, M; Dundar, Y; Boland, A
  • Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
    Hauschild, A; Grob, JJ; Demidov, LV; Jouary, T; Gutzmer, R; Millward, M
  • Adjusting for the confounding effects of treatment switching-the BREAK-3 trial: dabrafenib versus dacarbazine
    Latimer, NR; Abrams, KR; Amonkar, MM; Stapelkamp, C; Swann, RS
  • Improved survival with MEK inhibition in BRAF-mutated melanoma
    Flaherty, KT; Robert, C; Hersey, P; Nathan, P; Garbe, C; Milhem, M
  • Improved overall survival in melanoma with combined dabrafenib and trametinib
    Robert, C; Karaszewska, B; Schachter, J; Rutkowski, P; Mackiewicz, A; Stroiakovski, D
  • Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma
    Long, GV; Stroyakovskiy, D; Gogas, H; Levchenko, E; Braud, F; Larkin, J
  • Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
    Long, GV; Stroyakovskiy, D; Gogas, H; Levchenko, E; Braud, F; Larkin, J
  • Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
    Flaherty, KT; Infante, JR; Daud, A; Gonzalez, R; Kefford, RF; Sosman, J
  • Systematic review and indirect treatment comparison of dabrafenib and trametinib versus other treatments used in previously untreated metastatic melanoma patients
    Srivastava, K; Amonkar, MM; Ahuja, A; Stapelkamp, C; Swann, S; Casey, M
  • The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
    Liberati, A; Altman, DG; Tetzlaff, J; Mulrow, C; Gotzsche, PC; Ioannidis, JP
  • Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial
    Maio, M; Grob, JJ; Aamdal, S; Bondarenko, I; Robert, C; Thomas, L
  • Adjusting for confounding effects of treatment switching in a randomized phase II study of dabrafenib plus trametinib in BRAF V600+ metastatic melanoma
    Latimer, NR; Amonkar, MM; Stapelkamp, C; Sun, P
  • Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy
    Latimer, NR; Bell, H; Abrams, KR; Amonkar, MM; Casey, M
  • Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials
    Dias, S; Sutton, AJ; Ades, AE; Welton, NJ
  • Network meta-analysis of multiple outcome measures accounting for borrowing of information across outcomes
    Achana, FA; Cooper, NJ; Bujkiewicz, S; Hubbard, SJ; Kendrick, D; Jones, DR
  • Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials
    Flaherty, KT; Hennig, M; Lee, SJ; Ascierto, PA; Dummer, R; Eggermont, AM
  • Therapeutic efficacy of combined BRAF and MEK inhibition in metastatic melanoma: a comprehensive network meta-analysis of randomized controlled trials
    Mai, R; Zhou, S; Zhong, W; Rong, S; Cong, Z; Li, Y
  • Quantitative summaries of treatment effect estimates obtained with network meta-analysis of survival curves to inform decision-making
    Cope, S; Jansen, JP
  • Meta-regression models to address heterogeneity and inconsistency in network meta-analysis of survival outcomes
    Jansen, JP; Cope, S
  • Systematic review and network meta-analysis of overall survival comparing 3 mg/kg ipilimumab with alternative therapies in the management of pretreated patients with unresectable stage III or IV melanoma
    Dequen, P; Lorigan, P; Jansen, JP; Baardewijk, M; Ouwens, MJ; Kotapati, S
  • Network meta-analysis of parametric survival curves
    Ouwens, MJ; Philips, Z; Jansen, JP
  • A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma
    Hersh, EM; O’Day, SJ; Powderly, J; Khan, KD; Pavlick, AC; Cranmer, LD
  • A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
    Hamid, O; Schmidt, H; Nissan, A; Ridolfi, L; Aamdal, S; Hansson, J
  • Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
    Wolchok, JD; Neyns, B; Linette, G; Negrier, S; Lutzky, J; Thomas, L
  • Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma
    Long, GV; Menzies, AM; Nagrial, AM; Haydu, LE; Hamilton, AL; Mann, GJ
  • Association between NRAS and BRAF mutational status and melanoma-specific survival among patients with higher-risk primary melanoma
    Thomas, NE; Edmiston, SN; Alexander, A; Groben, PA; Parrish, E; Kricker, A
  • Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond
    Menzies, AM; Long, GV
  • BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival
    Hugdahl, E; Kalvenes, MB; Puntervoll, HE; Ladstein, RG; Akslen, LA
  • B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis
    Ugurel, S; Thirumaran, RK; Bloethner, S; Gast, A; Sucker, A; Mueller-Berghaus, J
  • Prognostic value of BRAF(V(6)(0)(0)) mutations in melanoma patients after resection of metastatic lymph nodes
    Moreau, S; Saiag, P; Aegerter, P; Bosset, D; Longvert, C; Helias-Rodzewicz, Z
  • Impact of BRAF V600 mutation in metastatic cutaneous melanoma patients treated with systemic therapy on brain metastases and survival
    Nowara, E; Nieckula, J; Badora-Rybicka, A; Rajczykowski, M; Huszno, J